[Onset and duration of action times for the new muscle relaxants vecuronium and atracurium. Comparison with pancuronium].

Chiara Melloni, L Pasini, Fabio Cataldi(Pfizer (United States)), L Ortelli, Maurizio Fusari

PubMed

June 1, 1988

Cited by 0

Related Papers

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

|The Lancet|2018|1.8k

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

|The Lancet|2023|350

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

|The Lancet|2017|198

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

|Gut|2015|157

Cockcroft-Gault Versus Modification of Diet in Renal Disease

|Journal of the American College of Cardiology|2008|135